(3) While we will attempt to control for common confounding factors such as age, gender, and baseline liver function, there may be other unmeasured factors (e.g., genetic predispositions, lifestyle habits, or co-infections) that could influence the treatment response and the success of Peg-IFN therapy. This evidence concerns the gene IFNA1 and coinfection.